Provided by Tiger Trade Technology Pte. Ltd.

Arrowhead Pharmaceuticals

82.41
+0.02000.02%
Volume:620.88K
Turnover:50.98M
Market Cap:11.61B
PE:-36.08
High:83.27
Open:81.14
Low:80.76
Close:82.39
52wk High:95.49
52wk Low:22.73
Shares:140.86M
Float Shares:122.00M
Volume Ratio:0.64
T/O Rate:0.51%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.2838
EPS(LYR):-0.0122
ROE:-55.21%
ROA:-8.10%
PB:24.94
PE(LYR):-6,758.80

Loading ...

Sep 14, 2021

Statement Of Changes In Beneficial Ownership

4 - Statement of changes in beneficial ownership of securities
Sep 10, 2021

Statement Of Changes In Beneficial Ownership

4 - Statement of changes in beneficial ownership of securities
Aug 27, 2021

Major Issues Report

ARROWHEAD PHARMACEUTICALS, INC.
Jun 25, 2021

Statement Of Changes In Beneficial Ownership

4 - Statement of changes in beneficial ownership of securities
Jun 22, 2021

Major Issues Report

8-K - Current report
Jun 16, 2021

Major Issues Report

8-K - Current report
May 18, 2021

Employee Stock Ownership

S-8 - Securities to be offered to employees in employee benefit plans
May 04, 2021

Quarterly Report

10-Q - Quarterly report [Sections 13 or 15(d)]
May 04, 2021

Major Issues Report

8-K - Current report
Mar 24, 2021

Major Issues Report

8-K - Current report
Feb 10, 2021

Beneficial Ownership Change

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
Feb 05, 2021

Correspondence

CORRESP [Cover] - Correspondence
Feb 04, 2021

Quarterly Report

10-Q - Quarterly report [Sections 13 or 15(d)]
Feb 04, 2021

Major Issues Report

8-K - Current report
Jan 27, 2021

Beneficial Ownership Change

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
Nov 23, 2020

Annual Report

10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
Nov 23, 2020

Major Issues Report

8-K - Current report
Oct 09, 2020

Major Issues Report

8-K - Current report
Sep 08, 2020

Major Issues Report

8-K - Current report
Aug 05, 2020

Quarterly Report

10-Q - Quarterly report [Sections 13 or 15(d)]